NCT06939595
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 5 words
- Site details revised
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 606 to confirmed 225
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence and severity of treatment-emergent adverse events (TEAEs) in the safety set
Timeframe: 12 months after the first dose of the last enrolled patient
Arms and interventions
CT-P51Experimental
EU-approved KeytrudaActive comparator
Drugs: CT-P51, EU-approved Keytruda
Sites
1 site in 1 country
- ltd "Institute of Clinical Oncology"Tbilisi, Georgia